BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bode FJ, Stephan M, Wiehager S, Nguyen HP, Björkqvist M, von Hörsten S, Bauer A, Petersén A. Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model. Behav Brain Res 2009;205:175-82. [PMID: 19573560 DOI: 10.1016/j.bbr.2009.06.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Jobert M, Wilson FJ, Roth T, Ruigt GS, Anderer P, Drinkenburg WH, Bes FW, Brunovsky M, Danker-Hopfe H, Freeman J, van Gerven JM, Gruber G, Kemp B, Klösch G, Ma J, Penzel T, Peterson BT, Schulz H, Staner L, Saletu B, Svetnik V; IPEG Pharmaco-EEG Guidelines Committee. Guidelines for the recording and evaluation of pharmaco-sleep studies in man: the International Pharmaco-EEG Society (IPEG). Neuropsychobiology 2013;67:127-67. [PMID: 23548759 DOI: 10.1159/000343449] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
2 Zarringhalam K, Ka M, Kook Y, Terranova JI, Suh Y, King OD, Um M. An open system for automatic home-cage behavioral analysis and its application to male and female mouse models of Huntington's disease. Behavioural Brain Research 2012;229:216-25. [DOI: 10.1016/j.bbr.2012.01.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
3 Wang HB, Whittaker DS, Truong D, Mulji AK, Ghiani CA, Loh DH, Colwell CS. Blue light therapy improves circadian dysfunction as well as motor symptoms in two mouse models of Huntington's disease. Neurobiol Sleep Circadian Rhythms 2017;2:39-52. [PMID: 31236494 DOI: 10.1016/j.nbscr.2016.12.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
4 Rieke L, Fels M, Schubert R, Habbel B, Matheis T, Schuldenzucker V, Kemper N, Reilmann R. Activity Behaviour of Minipigs Transgenic for the Huntington Gene. J Huntingtons Dis 2019;8:23-31. [PMID: 30689591 DOI: 10.3233/JHD-180325] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 van Wamelen DJ, Aziz NA. Hypothalamic pathology in Huntington disease. Handb Clin Neurol 2021;182:245-55. [PMID: 34266596 DOI: 10.1016/B978-0-12-819973-2.00017-4] [Reference Citation Analysis]
6 Nassan M, Videnovic A. Circadian rhythms in neurodegenerative disorders. Nat Rev Neurol 2021. [PMID: 34759373 DOI: 10.1038/s41582-021-00577-7] [Reference Citation Analysis]
7 Fisher SP, Black SW, Schwartz MD, Wilk AJ, Chen TM, Lincoln WU, Liu HW, Kilduff TS, Morairty SR. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease. Brain 2013;136:2159-72. [PMID: 23801738 DOI: 10.1093/brain/awt132] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
8 Kantor S, Szabo L, Varga J, Cuesta M, Morton AJ. Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation. Brain 2013;136:2147-58. [PMID: 23801737 DOI: 10.1093/brain/awt128] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
9 Fielding SA, Brooks SP, Klein A, Bayram-Weston Z, Jones L, Dunnett SB. Profiles of motor and cognitive impairment in the transgenic rat model of Huntington's disease. Brain Res Bull 2012;88:223-36. [PMID: 21963415 DOI: 10.1016/j.brainresbull.2011.09.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
10 Townhill J, Hughes AC, Thomas B, Busse ME, Price K, Dunnett SB, Hastings MH, Rosser AE. Using Actiwatch to monitor circadian rhythm disturbance in Huntington' disease: A cautionary note. J Neurosci Methods 2016;265:13-8. [PMID: 26774754 DOI: 10.1016/j.jneumeth.2016.01.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
11 van Wamelen DJ, Aziz NA, Roos RAC, Swaab DF. Hypothalamic Alterations in Huntington's Disease Patients: Comparison with Genetic Rodent Models. J Neuroendocrinol 2014;26:761-75. [DOI: 10.1111/jne.12190] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
12 Oakeshott S, Balci F, Filippov I, Murphy C, Port R, Connor D, Paintdakhi A, Lesauter J, Menalled L, Ramboz S, Kwak S, Howland D, Silver R, Brunner D. Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's Disease. PLoS Curr 2011;3:RRN1225. [PMID: 21479110 DOI: 10.1371/currents.RRN1225] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
13 Plank AC, Canneva F, Raber KA, Urbach YK, Dobner J, Puchades M, Bjaalie JG, Gillmann C, Bäuerle T, Riess O, Nguyen HHP, von Hörsten S. Early Alterations in Operant Performance and Prominent Huntingtin Aggregation in a Congenic F344 Rat Line of the Classical CAGn51trunc Model of Huntington Disease. Front Neurosci 2018;12:11. [PMID: 29422836 DOI: 10.3389/fnins.2018.00011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 2015;12:185-99. [PMID: 25252936 DOI: 10.1007/s13311-014-0304-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
15 Urbach YK, Raber KA, Canneva F, Plank AC, Andreasson T, Ponten H, Kullingsjö J, Nguyen HP, Riess O, von Hörsten S. Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington's disease. J Neurosci Methods 2014;234:38-53. [PMID: 25020253 DOI: 10.1016/j.jneumeth.2014.06.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
16 Wood NI, Carta V, Milde S, Skillings EA, McAllister CJ, Ang YL, Duguid A, Wijesuriya N, Afzal SM, Fernandes JX, Leong TW, Morton AJ. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease. PLoS One 2010;5:e9077. [PMID: 20174443 DOI: 10.1371/journal.pone.0009077] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
17 Smarr B, Cutler T, Loh DH, Kudo T, Kuljis D, Kriegsfeld L, Ghiani CA, Colwell CS. Circadian dysfunction in the Q175 model of Huntington's disease: Network analysis. J Neurosci Res 2019;97:1606-23. [PMID: 31359503 DOI: 10.1002/jnr.24505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Morton AJ. Circadian and sleep disorder in Huntington's disease. Exp Neurol 2013;243:34-44. [PMID: 23099415 DOI: 10.1016/j.expneurol.2012.10.014] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 9.4] [Reference Citation Analysis]
19 König C, Plank AC, Kapp A, Timotius IK, von Hörsten S, Zimmermann K. Thirty Mouse Strain Survey of Voluntary Physical Activity and Energy Expenditure: Influence of Strain, Sex and Day-Night Variation. Front Neurosci 2020;14:531. [PMID: 32733181 DOI: 10.3389/fnins.2020.00531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lundh SH, Soylu R, Petersén A. Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse. PLoS One 2012;7:e51168. [PMID: 23251447 DOI: 10.1371/journal.pone.0051168] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
21 Cutler TS, Park S, Loh DH, Jordan MC, Yokota T, Roos KP, Ghiani CA, Colwell CS. Neurocardiovascular deficits in the Q175 mouse model of Huntington's disease. Physiol Rep 2017;5:e13289. [PMID: 28576852 DOI: 10.14814/phy2.13289] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
22 Cuesta M, Aungier J, Morton AJ. Behavioral therapy reverses circadian deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis 2014;63:85-91. [PMID: 24269914 DOI: 10.1016/j.nbd.2013.11.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
23 Singer E, Hunanyan L, Melkonyan MM, Weber JJ, Danielyan L, Nguyen HP. The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease. Pharmaceuticals (Basel) 2021;14:257. [PMID: 33809220 DOI: 10.3390/ph14030257] [Reference Citation Analysis]
24 Paterson LM, Nutt DJ, Wilson SJ. Sleep and its disorders in translational medicine. J Psychopharmacol 2011;25:1226-34. [PMID: 21490119 DOI: 10.1177/0269881111400643] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
25 Videnovic A, Lazar AS, Barker RA, Overeem S. 'The clocks that time us'--circadian rhythms in neurodegenerative disorders. Nat Rev Neurol 2014;10:683-93. [PMID: 25385339 DOI: 10.1038/nrneurol.2014.206] [Cited by in Crossref: 175] [Cited by in F6Publishing: 164] [Article Influence: 21.9] [Reference Citation Analysis]
26 Cuesta M, Aungier J, Morton AJ. The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease. Neurobiol Dis 2012;45:145-55. [PMID: 21820053 DOI: 10.1016/j.nbd.2011.07.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
27 Videnovic A, Zee PC. Consequences of Circadian Disruption on Neurologic Health. Sleep Med Clin 2015;10:469-80. [PMID: 26568123 DOI: 10.1016/j.jsmc.2015.08.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]